Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after XXXX therapy in @entity1860 .

@entity1 @entity1860 @entity5 @entity2213
The current study investigated molecular cytogenetic characteristics of @entity1860 ( @entity1860 ) using genome-wide, single nucleotide polymorphism arrays (SNP-A) capable of detecting cryptic submicroscopic genomic aberrations. Genome-Wide @entity1 SNP 6.0 Array (Affymetrix, CA, USA) was performed in 118 @entity1 having @entity1860 , chronic phase. Thirty-nine clonal aberrations (CAs) were identified (35 losses, two gains, two copy neutral loss of heterozygosity) that were not detected by metaphase cytogenetics in 25 @entity1 (21%). The 9q34 deletions were found in 10% of cases, while 22q11.2 deletions were observed in 12% of cases. Seven @entity1 (6%) harbored both 5'-ABL and 3'-BCR deletions adjacent to the t(9;22) breakpoint. Copy number gains were identified at 8p and 9p, and losses at 2q, 7q, 8q, 9q, 11q, 13q, 16p, and 22q. When we compared the treatment outcome of @entity2213 therapy between @entity1 with and without CAs identified by SNP-A, treatment failure and progression to advanced disease were not significantly different (p   >   0.05). In addition, according to the presence of deletions of 9q34 and/or 22q11.2 identified by SNP-A, the treatment outcome did not show any significant differences (p   >   0.05). Our data suggests that SNP-A analysis is a useful tool for detection of clonal aberrations including deletions adjacent to the t(9;22) breakpoint in the @entity5 genome. However, clonal aberrations detected by SNP-A could not improve a prognostic stratification in @entity1860 @entity1 with chronic phase.
